BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community
The 2026 Oral Peptide Wave: What Approved Drugs, NDA Filings and Major Funding Rounds Mean for Research Procurement
A convergence of approvals, regulatory filings and investor capital is reshaping the oral peptide landscape in 2026. From orforglipron's April FDA clearance to Merck's NDA submission for an oral macrocyclic PCSK9 inhibitor and two oversubscribed platform financing rounds, the field is advancing along lines that will directly influence which peptide classes attract the most research attention — and procurement spend — over the next three years.
12 Jun 2026
Industry & Community
Peptide Platforms Attract Record Capital: What the Parabilis $670M IPO and 2026 Investment Surge Mean for Research Procurement
Parabilis Medicines closed the largest-ever venture-backed biotech IPO on 9 June 2026, raising $670 million for its Helicon helix-shaped peptide platform. Alongside a string of peptide-focused funding rounds, the capital surge signals a structural shift in how investors view peptide drug discovery — with direct implications for supply chains, platform technologies, and procurement priorities at UK research labs.
11 Jun 2026
Industry & Community
The Macrocyclic Peptide Investment Wave: What Three Major 2026 Deals Signal for the Research Landscape
A cluster of substantial deals in early 2026 — including Novartis's $100 million upfront commitment to Unnatural Products, Syneron Bio's $150 million Series B, and AstraZeneca's ongoing $3.4 billion biobucks arrangement — marks macrocyclic peptides as the modality attracting the most concentrated institutional attention in the peptide space. For research-procurement teams, understanding what distinguishes macrocycles from conventional linear peptides, and why big pharma is now paying platform…
30 May 2026
Industry & Community
Macrocyclic Peptides Draw Wave of Institutional Capital in 2026 as Big Pharma Targets "Undruggable" Biology
A cluster of deals in early 2026 has placed macrocyclic peptides at the centre of pharmaceutical dealmaking, with Syneron Bio closing a $150 million Series B, Novartis committing up to $1.8 billion to Unnatural Products, and AstraZeneca holding a strategic stake in the macrocycle space. For research-procurement teams, the surge signals where institutional confidence in the peptide modality is moving.
15 May 2026